| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 97 | 2024 | 4251 | 8.230 |
Why?
|
| Living Donors | 28 | 2022 | 620 | 3.000 |
Why?
|
| Kidney Failure, Chronic | 23 | 2023 | 2538 | 2.320 |
Why?
|
| BK Virus | 6 | 2021 | 129 | 2.110 |
Why?
|
| Polyomavirus Infections | 5 | 2021 | 197 | 1.800 |
Why?
|
| Pancreas Transplantation | 9 | 2023 | 187 | 1.700 |
Why?
|
| Tumor Virus Infections | 4 | 2021 | 452 | 1.560 |
Why?
|
| Graft Rejection | 28 | 2022 | 4397 | 1.540 |
Why?
|
| Donor Selection | 5 | 2022 | 201 | 1.470 |
Why?
|
| Tissue Donors | 15 | 2022 | 2240 | 1.460 |
Why?
|
| Immunosuppressive Agents | 17 | 2021 | 4149 | 1.030 |
Why?
|
| Tissue and Organ Procurement | 13 | 2019 | 896 | 1.030 |
Why?
|
| Graft Survival | 18 | 2023 | 3737 | 1.030 |
Why?
|
| Waiting Lists | 9 | 2023 | 692 | 1.030 |
Why?
|
| Glomerular Filtration Rate | 10 | 2023 | 2170 | 0.720 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2023 | 277 | 0.710 |
Why?
|
| Arteriovenous Fistula | 1 | 2023 | 315 | 0.710 |
Why?
|
| Cytomegalovirus Infections | 5 | 2018 | 820 | 0.670 |
Why?
|
| Diabetes Mellitus, Type 1 | 6 | 2023 | 3336 | 0.660 |
Why?
|
| Nephrectomy | 9 | 2020 | 1050 | 0.650 |
Why?
|
| Complement Factor H | 1 | 2018 | 110 | 0.650 |
Why?
|
| Glomerulonephritis | 2 | 2018 | 372 | 0.630 |
Why?
|
| Diabetic Nephropathies | 3 | 2021 | 984 | 0.630 |
Why?
|
| Kidney Function Tests | 4 | 2022 | 684 | 0.610 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2017 | 66 | 0.590 |
Why?
|
| Renal Dialysis | 6 | 2023 | 1786 | 0.530 |
Why?
|
| Creatinine | 7 | 2022 | 1919 | 0.520 |
Why?
|
| Sirolimus | 6 | 2010 | 1564 | 0.520 |
Why?
|
| Fibrinogen | 1 | 2018 | 894 | 0.520 |
Why?
|
| Kidney | 21 | 2023 | 7186 | 0.500 |
Why?
|
| Cytomegalovirus | 1 | 2018 | 732 | 0.480 |
Why?
|
| Organ Transplantation | 6 | 2021 | 1139 | 0.470 |
Why?
|
| Kidney Diseases | 4 | 2021 | 2149 | 0.470 |
Why?
|
| Tissue and Organ Harvesting | 8 | 2019 | 369 | 0.460 |
Why?
|
| Withholding Treatment | 1 | 2017 | 599 | 0.450 |
Why?
|
| Islets of Langerhans Transplantation | 2 | 2007 | 745 | 0.400 |
Why?
|
| Postoperative Complications | 13 | 2024 | 15295 | 0.400 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2017 | 1855 | 0.370 |
Why?
|
| Vital Signs | 1 | 2011 | 142 | 0.360 |
Why?
|
| Steroids | 3 | 2013 | 930 | 0.350 |
Why?
|
| Proteinuria | 4 | 2023 | 658 | 0.350 |
Why?
|
| Mycophenolic Acid | 3 | 2010 | 343 | 0.340 |
Why?
|
| Treatment Failure | 3 | 2010 | 2618 | 0.340 |
Why?
|
| Frail Elderly | 1 | 2014 | 693 | 0.330 |
Why?
|
| Humans | 122 | 2024 | 744343 | 0.330 |
Why?
|
| Liver Transplantation | 7 | 2022 | 2119 | 0.330 |
Why?
|
| Fatigue | 2 | 2019 | 1531 | 0.330 |
Why?
|
| Mandatory Testing | 1 | 2007 | 23 | 0.310 |
Why?
|
| Polycystic Kidney Diseases | 1 | 2009 | 133 | 0.310 |
Why?
|
| Critical Pathways | 1 | 2011 | 476 | 0.310 |
Why?
|
| Long-Term Care | 1 | 2011 | 607 | 0.300 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2007 | 168 | 0.270 |
Why?
|
| Patient Selection | 5 | 2012 | 4215 | 0.250 |
Why?
|
| Protease Inhibitors | 1 | 2009 | 791 | 0.250 |
Why?
|
| Quality of Life | 6 | 2023 | 12804 | 0.250 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2023 | 2208 | 0.240 |
Why?
|
| Boronic Acids | 1 | 2009 | 965 | 0.240 |
Why?
|
| Antiviral Agents | 5 | 2022 | 2987 | 0.240 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2019 | 3143 | 0.240 |
Why?
|
| HLA-DQ Antigens | 2 | 2018 | 210 | 0.230 |
Why?
|
| Mood Disorders | 1 | 2010 | 1106 | 0.230 |
Why?
|
| Biopsy | 8 | 2018 | 6756 | 0.230 |
Why?
|
| Registries | 1 | 2019 | 8089 | 0.230 |
Why?
|
| Pregnancy Complications | 1 | 2017 | 2861 | 0.230 |
Why?
|
| Prognosis | 11 | 2019 | 29063 | 0.220 |
Why?
|
| Advisory Committees | 2 | 2019 | 775 | 0.220 |
Why?
|
| Pyrazines | 1 | 2009 | 1230 | 0.220 |
Why?
|
| Hypertension | 1 | 2023 | 8480 | 0.220 |
Why?
|
| Diabetes Mellitus | 4 | 2012 | 5751 | 0.210 |
Why?
|
| Cardiovascular Diseases | 4 | 2023 | 15165 | 0.210 |
Why?
|
| Viremia | 2 | 2022 | 736 | 0.200 |
Why?
|
| Cysts | 1 | 2007 | 678 | 0.200 |
Why?
|
| House Calls | 2 | 2014 | 160 | 0.200 |
Why?
|
| Antilymphocyte Serum | 3 | 2013 | 492 | 0.200 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 2 | 2001 | 906 | 0.200 |
Why?
|
| Transplantation, Homologous | 8 | 2021 | 4776 | 0.200 |
Why?
|
| Hepatitis C, Chronic | 2 | 2022 | 1031 | 0.190 |
Why?
|
| Adult | 49 | 2023 | 214055 | 0.190 |
Why?
|
| Renal Insufficiency | 3 | 2018 | 804 | 0.190 |
Why?
|
| Cystatin C | 1 | 2022 | 250 | 0.190 |
Why?
|
| Prednisone | 2 | 2007 | 1574 | 0.190 |
Why?
|
| Survivors | 1 | 2011 | 2291 | 0.190 |
Why?
|
| Middle Aged | 43 | 2019 | 213383 | 0.180 |
Why?
|
| Kidney Glomerulus | 2 | 2018 | 697 | 0.180 |
Why?
|
| Patient Readmission | 1 | 2014 | 3114 | 0.180 |
Why?
|
| Nephrology | 1 | 2023 | 263 | 0.170 |
Why?
|
| Recurrence | 3 | 2018 | 8340 | 0.170 |
Why?
|
| Male | 47 | 2019 | 350118 | 0.170 |
Why?
|
| Virus Activation | 2 | 2019 | 319 | 0.170 |
Why?
|
| Liver Diseases | 1 | 2007 | 1253 | 0.160 |
Why?
|
| Complement Pathway, Alternative | 1 | 2018 | 126 | 0.160 |
Why?
|
| Pancreatic Diseases | 1 | 2020 | 350 | 0.160 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2002 | 1821 | 0.160 |
Why?
|
| Female | 48 | 2019 | 380194 | 0.160 |
Why?
|
| Follow-Up Studies | 13 | 2020 | 39050 | 0.150 |
Why?
|
| Histocompatibility Testing | 2 | 2018 | 741 | 0.150 |
Why?
|
| Delayed Graft Function | 1 | 2017 | 48 | 0.150 |
Why?
|
| Time Factors | 14 | 2019 | 40075 | 0.150 |
Why?
|
| Lung Transplantation | 3 | 2001 | 1153 | 0.150 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2022 | 525 | 0.150 |
Why?
|
| Retrospective Studies | 17 | 2022 | 77449 | 0.150 |
Why?
|
| Primary Graft Dysfunction | 1 | 2017 | 93 | 0.140 |
Why?
|
| Palliative Care | 1 | 2012 | 3493 | 0.140 |
Why?
|
| Complement Activation | 1 | 2018 | 453 | 0.140 |
Why?
|
| Podocytes | 1 | 2020 | 396 | 0.140 |
Why?
|
| Risk Factors | 11 | 2024 | 72290 | 0.140 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2017 | 132 | 0.140 |
Why?
|
| Stress, Psychological | 2 | 2010 | 4245 | 0.140 |
Why?
|
| Personal Satisfaction | 2 | 2018 | 643 | 0.130 |
Why?
|
| Ribavirin | 1 | 2016 | 395 | 0.120 |
Why?
|
| Mutation | 1 | 2018 | 29786 | 0.120 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2017 | 548 | 0.120 |
Why?
|
| Contraception | 1 | 2017 | 359 | 0.120 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 9438 | 0.120 |
Why?
|
| RNA, Messenger | 6 | 2022 | 13033 | 0.120 |
Why?
|
| Aged | 27 | 2020 | 163280 | 0.110 |
Why?
|
| Aftercare | 1 | 2019 | 866 | 0.110 |
Why?
|
| Body Image | 1 | 2018 | 610 | 0.110 |
Why?
|
| Sex Factors | 1 | 2006 | 10397 | 0.110 |
Why?
|
| Costs and Cost Analysis | 2 | 2016 | 1681 | 0.110 |
Why?
|
| Health Expenditures | 2 | 2016 | 2348 | 0.110 |
Why?
|
| Oral Ulcer | 2 | 2010 | 96 | 0.110 |
Why?
|
| Affect | 2 | 2018 | 1476 | 0.100 |
Why?
|
| Hepatitis C | 1 | 2022 | 1591 | 0.100 |
Why?
|
| Lost to Follow-Up | 1 | 2012 | 105 | 0.100 |
Why?
|
| Interleukins | 1 | 1996 | 791 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 9274 | 0.100 |
Why?
|
| Unemployment | 1 | 2013 | 214 | 0.100 |
Why?
|
| Cohort Studies | 5 | 2018 | 40561 | 0.100 |
Why?
|
| United States | 15 | 2022 | 69872 | 0.100 |
Why?
|
| Acute Disease | 6 | 2018 | 7149 | 0.100 |
Why?
|
| Risk Assessment | 6 | 2017 | 23338 | 0.100 |
Why?
|
| Reproduction | 2 | 2006 | 668 | 0.090 |
Why?
|
| Pedigree | 1 | 2018 | 4644 | 0.090 |
Why?
|
| Superinfection | 1 | 2010 | 65 | 0.090 |
Why?
|
| Bronchoalveolar Lavage Fluid | 3 | 2001 | 768 | 0.090 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 4186 | 0.090 |
Why?
|
| Analysis of Variance | 2 | 2017 | 6365 | 0.090 |
Why?
|
| Gene Expression | 4 | 1997 | 7799 | 0.090 |
Why?
|
| Treatment Outcome | 15 | 2019 | 63114 | 0.090 |
Why?
|
| Disease Transmission, Infectious | 1 | 2015 | 547 | 0.080 |
Why?
|
| Fear | 1 | 2018 | 1440 | 0.080 |
Why?
|
| Israel | 1 | 2011 | 796 | 0.080 |
Why?
|
| Social Adjustment | 1 | 2011 | 631 | 0.080 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2010 | 187 | 0.080 |
Why?
|
| Survival Rate | 4 | 2018 | 12788 | 0.080 |
Why?
|
| Standard of Care | 1 | 2012 | 564 | 0.080 |
Why?
|
| Blood Pressure | 2 | 2023 | 8554 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 12245 | 0.080 |
Why?
|
| Plasmapheresis | 1 | 2009 | 211 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 5 | 2010 | 6171 | 0.080 |
Why?
|
| Immune Tolerance | 1 | 2017 | 2258 | 0.080 |
Why?
|
| Renal Replacement Therapy | 1 | 2010 | 257 | 0.080 |
Why?
|
| Spouses | 1 | 2010 | 286 | 0.080 |
Why?
|
| Reoperation | 2 | 2009 | 4201 | 0.080 |
Why?
|
| Peritoneal Dialysis | 1 | 2009 | 146 | 0.080 |
Why?
|
| Immunity, Cellular | 2 | 2009 | 1607 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2017 | 4479 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2017 | 4386 | 0.070 |
Why?
|
| Ventilator Weaning | 1 | 2008 | 148 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2021 | 11725 | 0.070 |
Why?
|
| Mother-Child Relations | 1 | 2011 | 481 | 0.070 |
Why?
|
| Death | 2 | 2009 | 678 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2022 | 3923 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 6538 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2002 | 4751 | 0.070 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1995 | 2540 | 0.070 |
Why?
|
| Cardiac Tamponade | 1 | 2007 | 173 | 0.070 |
Why?
|
| Liver Cirrhosis | 1 | 2016 | 1863 | 0.070 |
Why?
|
| Prospective Studies | 9 | 2019 | 53288 | 0.070 |
Why?
|
| Lymphocyte Activation | 4 | 1998 | 5524 | 0.070 |
Why?
|
| Rupture | 1 | 2007 | 433 | 0.070 |
Why?
|
| Area Under Curve | 1 | 2010 | 1654 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 693 | 0.070 |
Why?
|
| Intubation | 1 | 2005 | 141 | 0.070 |
Why?
|
| Patient Education as Topic | 2 | 2013 | 2278 | 0.060 |
Why?
|
| Disclosure | 1 | 2011 | 736 | 0.060 |
Why?
|
| Health Services Accessibility | 2 | 2013 | 5137 | 0.060 |
Why?
|
| Candidiasis | 1 | 2007 | 366 | 0.060 |
Why?
|
| DNA | 1 | 2018 | 7301 | 0.060 |
Why?
|
| Survival Analysis | 1 | 2017 | 10252 | 0.060 |
Why?
|
| Granzymes | 3 | 2001 | 271 | 0.060 |
Why?
|
| Transplantation Immunology | 1 | 2006 | 546 | 0.060 |
Why?
|
| Immunity, Humoral | 1 | 2009 | 598 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2019 | 9146 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2013 | 4933 | 0.060 |
Why?
|
| Predictive Value of Tests | 4 | 2012 | 15076 | 0.060 |
Why?
|
| Polysomnography | 1 | 2010 | 1776 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2017 | 7729 | 0.060 |
Why?
|
| Decision Making | 1 | 2018 | 3887 | 0.060 |
Why?
|
| Chemokine CCL5 | 3 | 2002 | 209 | 0.060 |
Why?
|
| Mass Screening | 1 | 2019 | 5255 | 0.060 |
Why?
|
| HLA Antigens | 1 | 2009 | 1381 | 0.060 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2006 | 523 | 0.060 |
Why?
|
| Pore Forming Cytotoxic Proteins | 2 | 2000 | 130 | 0.050 |
Why?
|
| Interleukin-15 | 3 | 2002 | 184 | 0.050 |
Why?
|
| Healthcare Disparities | 3 | 2014 | 3158 | 0.050 |
Why?
|
| Cadaver | 4 | 2012 | 1337 | 0.050 |
Why?
|
| Recovery of Function | 2 | 2012 | 2925 | 0.050 |
Why?
|
| Perforin | 2 | 2000 | 168 | 0.050 |
Why?
|
| Pericardium | 1 | 2007 | 667 | 0.050 |
Why?
|
| Fas Ligand Protein | 2 | 2000 | 216 | 0.050 |
Why?
|
| Kidney Neoplasms | 1 | 2019 | 4262 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 1996 | 805 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2007 | 1850 | 0.050 |
Why?
|
| ROC Curve | 1 | 2010 | 3527 | 0.050 |
Why?
|
| Hypotension | 1 | 2008 | 884 | 0.050 |
Why?
|
| New England | 2 | 2020 | 1022 | 0.050 |
Why?
|
| Anemia | 1 | 2011 | 1506 | 0.050 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2002 | 171 | 0.050 |
Why?
|
| Attitude to Health | 1 | 2010 | 2052 | 0.050 |
Why?
|
| Transcription, Genetic | 5 | 2002 | 7722 | 0.050 |
Why?
|
| Renal Circulation | 1 | 2002 | 333 | 0.050 |
Why?
|
| Informed Consent | 1 | 2007 | 995 | 0.050 |
Why?
|
| Adolescent | 12 | 2015 | 85781 | 0.050 |
Why?
|
| Transplantation Conditioning | 1 | 2007 | 1598 | 0.050 |
Why?
|
| Cytokines | 4 | 2001 | 7322 | 0.050 |
Why?
|
| Pandemics | 1 | 2020 | 8388 | 0.050 |
Why?
|
| Device Removal | 1 | 2005 | 656 | 0.050 |
Why?
|
| Serine Endopeptidases | 3 | 2001 | 1072 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2009 | 2035 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 4 | 2019 | 7279 | 0.050 |
Why?
|
| Urinary Bladder | 1 | 2006 | 1172 | 0.050 |
Why?
|
| Ganciclovir | 1 | 2000 | 258 | 0.040 |
Why?
|
| Comorbidity | 2 | 2020 | 10388 | 0.040 |
Why?
|
| Acyclovir | 1 | 2000 | 272 | 0.040 |
Why?
|
| Clinical Protocols | 2 | 2018 | 1462 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2009 | 1580 | 0.040 |
Why?
|
| Body Weight | 1 | 2010 | 4669 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 634 | 0.040 |
Why?
|
| Caregivers | 1 | 2010 | 2094 | 0.040 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2020 | 494 | 0.040 |
Why?
|
| Polyenes | 1 | 1998 | 69 | 0.040 |
Why?
|
| Pregnancy | 3 | 2017 | 29144 | 0.040 |
Why?
|
| Antibodies, Viral | 2 | 2022 | 3176 | 0.040 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2002 | 357 | 0.040 |
Why?
|
| Cross-Sectional Studies | 4 | 2014 | 25043 | 0.040 |
Why?
|
| Dialysis | 1 | 2017 | 75 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2012 | 3022 | 0.040 |
Why?
|
| Base Sequence | 4 | 2017 | 12797 | 0.040 |
Why?
|
| Cold Ischemia | 1 | 2018 | 65 | 0.040 |
Why?
|
| Laparoscopy | 2 | 2006 | 2151 | 0.040 |
Why?
|
| Nitric Oxide Synthase | 1 | 2000 | 916 | 0.040 |
Why?
|
| Reference Values | 2 | 2002 | 4982 | 0.040 |
Why?
|
| T-Lymphocytes | 4 | 1998 | 10180 | 0.040 |
Why?
|
| Attitude | 1 | 2022 | 776 | 0.040 |
Why?
|
| Histocompatibility | 1 | 1998 | 330 | 0.040 |
Why?
|
| Interleukin-2 | 3 | 2002 | 1904 | 0.040 |
Why?
|
| HLA-DR Antigens | 1 | 2018 | 645 | 0.030 |
Why?
|
| Ischemia | 1 | 2005 | 1907 | 0.030 |
Why?
|
| Health Care Surveys | 2 | 2018 | 2453 | 0.030 |
Why?
|
| Age Distribution | 2 | 2015 | 2902 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2014 | 9959 | 0.030 |
Why?
|
| Boston | 3 | 2015 | 9313 | 0.030 |
Why?
|
| Morbidity | 1 | 2021 | 1769 | 0.030 |
Why?
|
| Health Surveys | 2 | 2020 | 4037 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2002 | 1434 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2001 | 1609 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2022 | 1379 | 0.030 |
Why?
|
| Pancreas | 1 | 2021 | 1686 | 0.030 |
Why?
|
| Substance-Related Disorders | 1 | 2011 | 4258 | 0.030 |
Why?
|
| Coronary Artery Disease | 2 | 2019 | 6487 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2002 | 2007 | 0.030 |
Why?
|
| Decision Support Techniques | 2 | 2015 | 1956 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2014 | 513 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2001 | 5179 | 0.030 |
Why?
|
| Hospitals, University | 2 | 2009 | 571 | 0.030 |
Why?
|
| DNA Primers | 1 | 2017 | 2892 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2005 | 2788 | 0.030 |
Why?
|
| Chemokines | 1 | 1997 | 970 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1996 | 1369 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2017 | 1880 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 1996 | 1950 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2005 | 3679 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 1978 | 0.030 |
Why?
|
| Membrane Glycoproteins | 2 | 2000 | 3768 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 1995 | 2050 | 0.030 |
Why?
|
| Immunoconjugates | 1 | 1998 | 901 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2012 | 426 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2002 | 11366 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2017 | 2225 | 0.020 |
Why?
|
| Role | 1 | 2010 | 175 | 0.020 |
Why?
|
| Young Adult | 5 | 2015 | 56430 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2016 | 6489 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2001 | 5974 | 0.020 |
Why?
|
| Antigen Presentation | 1 | 1996 | 1284 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 2020 | 1643 | 0.020 |
Why?
|
| Interleukin-7 | 2 | 2002 | 142 | 0.020 |
Why?
|
| Cell Line | 3 | 2001 | 15997 | 0.020 |
Why?
|
| Glucose | 1 | 2021 | 4397 | 0.020 |
Why?
|
| Cultural Competency | 1 | 2012 | 289 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2021 | 2872 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2019 | 2266 | 0.020 |
Why?
|
| Regression Analysis | 2 | 2014 | 6459 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 1997 | 18111 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2012 | 20129 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 4560 | 0.020 |
Why?
|
| Child | 8 | 2009 | 77709 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2020 | 3444 | 0.020 |
Why?
|
| Actuarial Analysis | 2 | 1998 | 378 | 0.020 |
Why?
|
| Incidence | 2 | 2020 | 20947 | 0.020 |
Why?
|
| Rabbits | 1 | 2013 | 4894 | 0.020 |
Why?
|
| Heart Transplantation | 1 | 2000 | 3110 | 0.020 |
Why?
|
| Calcium | 1 | 2020 | 5756 | 0.020 |
Why?
|
| Proteins | 1 | 2002 | 6103 | 0.020 |
Why?
|
| Family | 2 | 2008 | 3147 | 0.020 |
Why?
|
| HIV Infections | 1 | 2013 | 16718 | 0.020 |
Why?
|
| Cyclosporine | 1 | 2009 | 786 | 0.020 |
Why?
|
| Neoplasms | 1 | 2015 | 21683 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2020 | 25625 | 0.020 |
Why?
|
| Tacrolimus | 1 | 2009 | 743 | 0.020 |
Why?
|
| Albuminuria | 1 | 2009 | 682 | 0.020 |
Why?
|
| Patient Participation | 1 | 2014 | 1457 | 0.020 |
Why?
|
| Lymphocyte Cooperation | 1 | 1984 | 112 | 0.020 |
Why?
|
| Health Personnel | 1 | 2018 | 3218 | 0.020 |
Why?
|
| Mitochondria | 1 | 2017 | 3520 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 2007 | 1150 | 0.020 |
Why?
|
| Algorithms | 2 | 2015 | 13881 | 0.010 |
Why?
|
| Animals | 4 | 2013 | 168757 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 2005 | 520 | 0.010 |
Why?
|
| Reperfusion | 1 | 2005 | 284 | 0.010 |
Why?
|
| Socioeconomic Factors | 2 | 2008 | 7785 | 0.010 |
Why?
|
| Medical History Taking | 1 | 2007 | 783 | 0.010 |
Why?
|
| Contraceptives, Oral | 1 | 2006 | 564 | 0.010 |
Why?
|
| Age Factors | 3 | 2008 | 18370 | 0.010 |
Why?
|
| Prevalence | 1 | 2020 | 15226 | 0.010 |
Why?
|
| Patient-Centered Care | 1 | 2013 | 1439 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 1996 | 4665 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2014 | 3396 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2012 | 2645 | 0.010 |
Why?
|
| Macrophages | 1 | 1996 | 5655 | 0.010 |
Why?
|
| Gene Expression Regulation | 2 | 1998 | 12072 | 0.010 |
Why?
|
| Cost of Illness | 1 | 2010 | 1859 | 0.010 |
Why?
|
| Social Support | 1 | 2010 | 2118 | 0.010 |
Why?
|
| Receptors, Interleukin | 1 | 2002 | 245 | 0.010 |
Why?
|
| Risk | 1 | 2013 | 9687 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 2002 | 411 | 0.010 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2002 | 310 | 0.010 |
Why?
|
| Intubation, Intratracheal | 1 | 2008 | 1364 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2018 | 21746 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 2010 | 2576 | 0.010 |
Why?
|
| Health Status Disparities | 1 | 2011 | 1797 | 0.010 |
Why?
|
| Heme Oxygenase-1 | 1 | 2002 | 381 | 0.010 |
Why?
|
| Logistic Models | 1 | 2014 | 13408 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2002 | 690 | 0.010 |
Why?
|
| Prenatal Care | 1 | 2006 | 1092 | 0.010 |
Why?
|
| Psychometrics | 1 | 2008 | 3002 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2000 | 534 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 2002 | 1147 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2000 | 1420 | 0.010 |
Why?
|
| Nephrotic Syndrome | 1 | 2002 | 389 | 0.010 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2002 | 644 | 0.010 |
Why?
|
| Child, Preschool | 3 | 2009 | 41006 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2007 | 2531 | 0.010 |
Why?
|
| Research Design | 1 | 2012 | 5987 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 6234 | 0.010 |
Why?
|
| Interleukin-17 | 1 | 2002 | 899 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1996 | 517 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 1998 | 927 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2009 | 6256 | 0.010 |
Why?
|
| Organ Preservation | 1 | 1997 | 331 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 1996 | 421 | 0.010 |
Why?
|
| Cold Temperature | 1 | 1997 | 772 | 0.010 |
Why?
|
| California | 1 | 1997 | 1402 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2000 | 3913 | 0.010 |
Why?
|
| Infant | 2 | 2009 | 35136 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2002 | 2915 | 0.010 |
Why?
|
| Physicians | 1 | 2009 | 4567 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1998 | 1951 | 0.010 |
Why?
|
| Surgical Wound Infection | 1 | 2000 | 1540 | 0.010 |
Why?
|
| Kinetics | 1 | 1998 | 6473 | 0.010 |
Why?
|
| RNA | 1 | 2000 | 2749 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 1996 | 1783 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 19905 | 0.010 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1996 | 1366 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1998 | 6622 | 0.010 |
Why?
|
| Antigens, CD | 1 | 1998 | 4026 | 0.000 |
Why?
|
| Nuclear Proteins | 1 | 2002 | 5853 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 57776 | 0.000 |
Why?
|
| Obesity | 1 | 2007 | 12745 | 0.000 |
Why?
|
| Hemolytic Plaque Technique | 1 | 1984 | 66 | 0.000 |
Why?
|
| Membrane Proteins | 1 | 2002 | 7880 | 0.000 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 9648 | 0.000 |
Why?
|
| Antibody-Producing Cells | 1 | 1984 | 143 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1998 | 19229 | 0.000 |
Why?
|
| Sheep | 1 | 1984 | 1437 | 0.000 |
Why?
|
| Clone Cells | 1 | 1984 | 1692 | 0.000 |
Why?
|
| Antigens, Surface | 1 | 1984 | 1663 | 0.000 |
Why?
|
| Spleen | 1 | 1984 | 2362 | 0.000 |
Why?
|
| Cell Adhesion | 1 | 1984 | 3144 | 0.000 |
Why?
|
| Mice, Inbred BALB C | 1 | 1984 | 6386 | 0.000 |
Why?
|
| Phenotype | 1 | 1984 | 16365 | 0.000 |
Why?
|
| Mice, Inbred C57BL | 1 | 1984 | 21827 | 0.000 |
Why?
|
| Mice | 1 | 1984 | 81183 | 0.000 |
Why?
|